Oral Sirolimus for Diffuse Choroidal Hemangioma in Sturge-Weber Syndrome

Amy Kalantary; Anne Halbert; Maria Franchina; Rachael C Heath Jeffery; Rod O'Day; Fred K Chen

doi:10.1001/jamaophthalmol.2024.0854

Oral Sirolimus for Diffuse Choroidal Hemangioma in Sturge-Weber Syndrome

JAMA Ophthalmol. 2024 Jun 1;142(6):585-587. doi: 10.1001/jamaophthalmol.2024.0854.

Authors

Amy Kalantary¹, Anne Halbert², Maria Franchina^{2

3}, Rachael C Heath Jeffery^{1

3

4}, Rod O'Day^{4

5}, Fred K Chen^{1

2

3

4

5}

Affiliations

¹ Lions Eye Institute, Nedlands, Western Australia, Australia.
² Perth Children's Hospital, Nedlands, Western Australia, Australia.
³ Centre for Ophthalmology and Visual Science, The University of Western Australia, Crawley, Western Australia, Australia.
⁴ Royal Victorian Eye and Ear Hospital (Centre for Eye Research Australia), East Melbourne, Victoria, Australia.
⁵ Ophthalmology, Department of Surgery, University of Melbourne, East Melbourne, Victoria, Australia.

PMID: 38635233
DOI: 10.1001/jamaophthalmol.2024.0854

No abstract available

Plain language summary

This case report describes an 8-year-old girl who received oral sirolimus as an adjuvant therapy for pulse dye laser of her port-wine stain and as an off-label treatment of exudative retinal detachment secondary to diffuse choroidal hemangioma.

Publication types

Case Reports

MeSH terms

Administration, Oral
Choroid Neoplasms* / diagnosis
Choroid Neoplasms* / drug therapy
Fluorescein Angiography
Hemangioma / diagnosis
Hemangioma / drug therapy
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / therapeutic use
Sirolimus* / administration & dosage
Sturge-Weber Syndrome* / complications
Sturge-Weber Syndrome* / diagnosis
Sturge-Weber Syndrome* / drug therapy

Substances

Immunosuppressive Agents
Sirolimus